Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
581-600 of 1,694 trials

Chronic Lymphocytic Leukemia: Pirtobrutinib vs. Ibrutinib

We are comparing the effectiveness of pirtobrutinib to ibrutinib in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. This study also focuses on those who are newly diagnosed and have a specific genetic change.

Chronic Lymphocytic Leukemia6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Rheumatoid Arthritis: MethMax Trial

We are studying how well methotrexate works for people with active rheumatoid arthritis. The goal is to see if it helps more patients reach remission or low disease activity compared to current treatments.

Rheumatoid Arthritis3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Opioid-Induced Bowel Dysfunction: Naldemedine Study

We are investigating how naldemedine affects bowel function in individuals using opioids like tramadol. The goal is to see if it improves gastrointestinal movement and overall bowel health.

Opioid Induced Bowel Dysfunction≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Multiple Myeloma: BGB-11417 Treatment Study

We are investigating the safety and effectiveness of BGB-11417 alone and with other medications for patients with relapsed or refractory multiple myeloma. This study aims to find the best treatment options for those with a specific genetic marker.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

MK-1084 with Pembrolizumab for Metastatic Lung Cancer

We are studying a new treatment combination for patients with KRAS G12C-mutant metastatic lung cancer. The goal is to see if it works better than standard treatment in improving survival and quality of life.

Non-small cell lung cancer>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementOncology

Coronary Artery Spasm: Testing Bosentan

We are studying whether the medication bosentan can help reduce coronary artery spasms in patients with ongoing angina symptoms. The trial also aims to evaluate its effects on quality of life and safety.

Coronary Vasospasm≤3 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Cirrhosis and Ascites: Fecal Microbiota Transfer Capsules

We are testing the safety of FMT capsules for patients with cirrhosis and ascites to see if they may help reduce immune activation. This study will also look for signs of effectiveness compared to a placebo.

Cirrhosis of the Liver1-2 yearsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyHepatology

Childhood Epilepsy: Perampanel Treatment Study

We are studying the effects of perampanel, given with other epilepsy medications, in children under 18. The goal is to see if it helps reduce seizures and improve overall health and development.

Childhood EpilepsyEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyPediatrics

Pulmonary Embolism: Surveillance vs. Anticoagulation

We are studying whether monitoring without blood thinners is as safe and effective as using them for low-risk patients with isolated subsegmental pulmonary embolism. This trial will also assess side effects and quality of life for participants.

Isolated Subsegmental Pulmonary Embolism3-6 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesPartially RemoteCardiologyPulmonology

Peripheral T-Cell Lymphoma: New Drug Combinations

We are studying whether combining Beleodaq or Folotyn with standard chemotherapy is more effective for newly diagnosed patients with Peripheral T-Cell Lymphoma. The goal is to see if these combinations improve treatment outcomes compared to standard therapy alone.

Peripheral T-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Linvoseltamab for Relapsed or Refractory AL Amyloidosis

We are studying whether linvoseltamab is safe and effective for adults with relapsed or refractory systemic light chain amyloidosis. The trial will help us understand its impact on blood response and overall health.

Relapsed or Refractory Systemic Light Chain Amyloidosis>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyInternal Medicine

Pancreatic Exocrine Insufficiency: Creon® Therapy Study

We are exploring how Creon® may help improve nutrition and quality of life for patients with pancreatic exocrine insufficiency after total gastrectomy. The study also looks at weight changes and gastrointestinal symptoms.

Pancreatic Exocrine Insufficiency1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Hormonal Contraceptives: Brain Effects Study

We are comparing two types of hormonal contraceptives to see how they affect brain structure and function. We're also looking at their impact on quality of life and mental health symptoms.

Hormonal Contraception≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsNeurology

Cannabidiol for Refractory Childhood Epilepsy

We are studying whether adding CBD can help children with hard-to-treat epilepsy manage their seizures better. The trial also looks at how this treatment affects the quality of life for patients and their families.

Refractory Epilepsy1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Hot Flashes After Breast Cancer: Oxybutynin vs. Venlafaxine

We are studying whether oxybutynin or venlafaxine is more effective in reducing hot flashes in women using endocrine therapy after breast cancer. We will also look at side effects and personal preferences between the two treatments.

Estrogen Receptor Positive Breast Cancer3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyOncology

Multiple Myeloma: Elranatamab vs. Standard Treatments

We are studying a new treatment called elranatamab for people with relapsed refractory multiple myeloma. The goal is to see how well it works compared to current therapies and to assess its safety and impact on quality of life.

Relapsed/Refractory Multiple MyelomaConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Acute Myeloid Leukemia: Gilteritinib with Venetoclax and Azacitidine

We are studying a combination of three medications for patients with newly diagnosed acute myeloid leukemia and FLT3 mutations who cannot receive intensive treatment. The goal is to find the best dose that is safe and effective.

Acute Myeloid LeukemiaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Systemic Juvenile Idiopathic Arthritis: Baricitinib Study

We are studying the effectiveness of baricitinib in children aged 1 to under 18 with systemic juvenile idiopathic arthritis. This research aims to find out if it helps improve their condition.

Systemic Juvenile Idiopathic Arthritis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Advanced Cancer: Targeted Drug Study

We are investigating whether approved cancer drugs can help patients with advanced cancer who have specific genetic markers. This study aims to improve treatment options by using these drugs in new ways.

CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Esophageal Strictures: Budesonide Tablets

We are studying whether budesonide tablets can help prevent esophageal strictures in adults after cancer surgery. This trial compares two doses of the medication to a placebo to assess effectiveness and safety.

Oesophageal Cancer and Related Conditions>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesGastroenterologyOncology